Home > Publications Database > Detection of Cerebral Microbleeds With Venous Connection at 7-Tesla MRI. > print

001     157814
005     20240305154120.0
024 7 _ |a 10.1212/WNL.0000000000011790
|2 doi
024 7 _ |a pmid:33653897
|2 pmid
024 7 _ |a 0028-3878
|2 ISSN
024 7 _ |a 1526-632X
|2 ISSN
024 7 _ |a altmetric:101224786
|2 altmetric
037 _ _ |a DZNE-2021-01271
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Rotta, Johanna
|b 0
245 _ _ |a Detection of Cerebral Microbleeds With Venous Connection at 7-Tesla MRI.
260 _ _ |a [S.l.]
|c 2021
|b Ovid
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1709649657_29110
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Cerebral microbleeds (MBs) are a common finding in patients with cerebral small vessel disease (CSVD) and Alzheimer disease as well as in healthy elderly people, but their pathophysiology remains unclear. To investigate a possible role of veins in the development of MBs, we performed an exploratory study, assessing in vivo presence of MBs with a direct connection to a vein.7-Tesla (7T) MRI was conducted and MBs were counted on quantitative susceptibility mapping (QSM). A submillimeter resolution QSM-based venogram allowed identification of MBs with a direct spatial connection to a vein.A total of 51 people (mean age [SD] 70.5 [8.6] years, 37% female) participated in the study: 20 had CSVD (cerebral amyloid angiopathy [CAA] with strictly lobar MBs [n = 8], hypertensive arteriopathy [HA] with strictly deep MBs [n = 5], or mixed lobar and deep MBs [n = 7], 72.4 [6.1] years, 30% female) and 31 were healthy controls (69.4 [9.9] years, 42% female). In our cohort, we counted a total of 96 MBs with a venous connection, representing 14% of all detected MBs on 7T QSM. Most venous MBs (86%, n = 83) were observed in lobar locations and all of these were cortical. Patients with CAA showed the highest ratio of venous to total MBs (19%) (HA = 9%, mixed = 18%, controls = 5%).Our findings establish a link between cerebral MBs and the venous vasculature, pointing towards a possible contribution of veins to CSVD in general and to CAA in particular. Pathologic studies are needed to confirm our observations.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Cerebral Hemorrhage: diagnostic imaging
|2 MeSH
650 _ 2 |a Cerebral Hemorrhage: etiology
|2 MeSH
650 _ 2 |a Cerebral Hemorrhage: pathology
|2 MeSH
650 _ 2 |a Cerebral Small Vessel Diseases: complications
|2 MeSH
650 _ 2 |a Cerebral Small Vessel Diseases: pathology
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Image Interpretation, Computer-Assisted
|2 MeSH
650 _ 2 |a Magnetic Resonance Imaging
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Neuroimaging: methods
|2 MeSH
650 _ 2 |a Veins: diagnostic imaging
|2 MeSH
650 _ 2 |a Veins: pathology
|2 MeSH
700 1 _ |a Perosa, Valentina
|0 P:(DE-2719)9000985
|b 1
|u dzne
700 1 _ |a Yakupov, Renat
|0 P:(DE-2719)2812398
|b 2
|u dzne
700 1 _ |a Kuijf, Hugo J
|0 0000-0001-6997-9059
|b 3
700 1 _ |a Schreiber, Frank
|0 P:(DE-2719)9000986
|b 4
|u dzne
700 1 _ |a Dobisch, Laura
|0 P:(DE-2719)2811611
|b 5
|u dzne
700 1 _ |a Oltmer, Jan
|0 P:(DE-2719)2811736
|b 6
|u dzne
700 1 _ |a Assmann, Anne
|0 P:(DE-2719)2812914
|b 7
|u dzne
700 1 _ |a Speck, Oliver
|0 P:(DE-2719)2810706
|b 8
|u dzne
700 1 _ |a Heinze, Hans-Jochen
|0 P:(DE-2719)2260426
|b 9
|u dzne
700 1 _ |a Acosta-Cabronero, Julio
|0 P:(DE-2719)2810751
|b 10
|u dzne
700 1 _ |a Düzel, Emrah
|0 P:(DE-2719)2000005
|b 11
|u dzne
700 1 _ |a Schreiber, Stefanie
|0 P:(DE-2719)2812631
|b 12
|e Last author
|u dzne
773 _ _ |a 10.1212/WNL.0000000000011790
|g Vol. 96, no. 16, p. e2048 - e2057
|0 PERI:(DE-600)1491874-2
|n 16
|p e2048 - e2057
|t Neurology
|v 96
|y 2021
|x 1526-632X
909 C O |p VDB
|o oai:pub.dzne.de:157814
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 1
|6 P:(DE-2719)9000985
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 2
|6 P:(DE-2719)2812398
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 4
|6 P:(DE-2719)9000986
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 5
|6 P:(DE-2719)2811611
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 6
|6 P:(DE-2719)2811736
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 7
|6 P:(DE-2719)2812914
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 8
|6 P:(DE-2719)2810706
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 9
|6 P:(DE-2719)2260426
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 10
|6 P:(DE-2719)2810751
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 11
|6 P:(DE-2719)2000005
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 12
|6 P:(DE-2719)2812631
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2021
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-01-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2021-01-27
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-01-27
915 _ _ |a Allianz-Lizenz
|0 StatID:(DE-HGF)0410
|2 StatID
|d 2022-11-12
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2022-11-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2022-11-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2022-11-12
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b NEUROLOGY : 2021
|d 2022-11-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-12
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b NEUROLOGY : 2021
|d 2022-11-12
920 1 _ |0 I:(DE-2719)5000006
|k AG Düzel
|l Clinical Neurophysiology and Memory
|x 0
920 1 _ |0 I:(DE-2719)1310010
|k AG Schreiber
|l Mixed Cerebral Pathologies and Cognitive Aging
|x 1
920 1 _ |0 I:(DE-2719)1340009
|k AG Speck
|l Linking imaging projects iNET
|x 2
920 1 _ |0 I:(DE-2719)1310002
|k AG Wolbers
|l Aging, Cognition and Technology
|x 3
920 1 _ |0 I:(DE-2719)1310001
|k AG Nestor
|l Cognitive Neurology and Neurodegeneration
|x 4
920 1 _ |0 I:(DE-2719)7000000
|k U Clinical Researchers - Magdeburg
|l U Clinical Researchers - Magdeburg
|x 5
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-2719)5000006
980 _ _ |a I:(DE-2719)1310010
980 _ _ |a I:(DE-2719)1340009
980 _ _ |a I:(DE-2719)1310002
980 _ _ |a I:(DE-2719)1310001
980 _ _ |a I:(DE-2719)7000000
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21